Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/1/1996
1.
Phase III Randomized Study of Liarozole Fumarate (R85246) vs PRED for Metastatic, Hormone-Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
YALE-HIC-7586
NCI-V95-0727
Last Modified:
7/1/1998
2.
Phase II Study of Liarozole Fumarate for Unresectable or Metastatic Breast Cancer (Summary Last Modified 07/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
postmenopausal
EORTC-10941
Last Modified:
6/1/1997
3.
Phase II Pilot Study of Liarozole in Myelodysplastic Syndrome (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Other
JRF-LIA-USA-31
NCI-V95-0745
Last Modified:
6/1/1997
4.
Phase II Pilot Study of Liarozole in Progressive or Recurrent Squamous Cell Carcinoma of the Cervix (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Other
JRF-LIA-USA-25
NCI-V95-0746
Last Modified:
8/1/1996
5.
Phase II Pilot Study of Liarozole Fumarate for Recurrent non-Small Cell Lung Cancer (Summary Last Modified 08/96)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
YALE-HIC-8592
NCI-V96-0889
Last Modified:
2/1/1998
6.
Phase II Randomized, Double-Blind Study of 3 Doses of Liarozole Fumarate in Patients with Rising PSA Levels After Definitive Local Treatment for Stage I/II/III Prostate Cancer (Summary Last Modified 02/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
JRF-LIA-INT-26
NCI-V97-1121
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute